Jpmorgan Chase & CO Red Hill Biopharma Ltd. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.14 - $695.9 $361 - $1.8 Million	-2,585 Reduced 88.68%	330 $0
Q3 2022 Nov 14, 2022	BUY	$0.5 - $523.8 $410 - $429,515	820 Added 39.14%	2,915 $1,000
Q2 2022 Aug 11, 2022	SELL	$0.63 - $2.58 $2,449 - $10,031	-3,888 Reduced 64.98%	2,095 $2,000
Q1 2022 May 11, 2022	BUY	$1.65 - $3.12 $2,366 - $4,474	1,434 Added 31.52%	5,983 $15,000
Q4 2021 Feb 10, 2022	SELL	$2.31 - $5.85 $94,961 - $240,487	-41,109 Reduced 90.04%	4,549 $12,000
Q3 2021 Nov 12, 2021	BUY	$4.55 - $10.36 $207,743 - $473,016	45,658 New	45,658 $209,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.